Sagent Pharmaceuticals has launched Vancomycin Hydrochloride for injection, USP, an anti-infective, in a 5gm pharmacy bulk package mode.
Vancomycin is designed to help reduce medication errors and features the company's PreventIV Measures packaging and labeling.
The injection is used to treat infections caused by susceptible strains of methicillin-resistant (beta lactam-resistant) staphylococci for penicillin, cephalosporins allergic patients.
It is also used to treat the infections caused by vancomycin-susceptible organisms, which are resistant to other antimicrobial drugs.
The US market for Vancomycin Hydrochloride for injection, USP was nearly $186m out of which nearly 50% of the sales was pharmacy bulk packages for the 12 months ending June 2012, according to IMS.
